Stride Gets Approval for Gabapentin Tablet

Stride Gets Approval for Gabapentin Tablet

By, Admin 6 March 2024

Strides receives US FDA approval for gabapentin tablets USP, 600 & 800 mg

Strides Pharma Science has announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for gabapentin tablets USP, 600 mg and 800 mg, from the United States Food & Drug Administration (FDA).
 
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin tablets, 600 mg and 800 mg, of Viatris Specialty LLC.

Gabapentin Market Size

  • Gabapentin tablets has a market size of ~US$ 140 million as per IMS. 
  • This approval further strengthens the company's presence in the gabapentin portfolio, complementing the existing approval of gabapentin capsules, which has a market size of US$ 208 million. 
  • The gabapentin tablets will be manufactured at the company’s facility in Puducherry.
  • ANDA filings 
  • The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with US FDA, of which 235+ ANDAs have been approved. 
  • The company has set a target to launch ~ 60 new products over three years in the US.

About Gabapentin

Gabapentin is an anticonvulsant medication primarily used to treat partial seizures and neuropathic pain. It is a commonly used medication for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!